Phase 2 Study of Orlistat and SLx-4090 for Teh Treatment of Type 1 Hyperlipoproteinemia

Trial Profile

Phase 2 Study of Orlistat and SLx-4090 for Teh Treatment of Type 1 Hyperlipoproteinemia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs KD 026 (Primary) ; Orlistat
  • Indications Hyperlipoproteinaemia type I
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Jun 2017 Planned End Date changed from 1 Dec 2017 to 31 Jul 2019.
    • 16 Jun 2017 Planned primary completion date changed from 1 Dec 2017 to 31 Jul 2019.
    • 03 Dec 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top